Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Nurix Therapeutics ( (NRIX) ) is now available.
On December 6 and 8, 2025, Nurix Therapeutics announced new clinical data from its Phase 1a/1b study of the BTK degrader bexobrutideg (NX-5948) at the 67th American Society of Hematology Annual Meeting. The data showed promising efficacy and safety results in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and Waldenström macroglobulinemia (WM). The study highlighted an objective response rate of 83% in CLL patients and a disease control rate of 95.7%, with the 600 mg dose showing higher response rates and longer progression-free survival compared to the 200 mg dose. These findings support the advancement of the 600 mg dose into further clinical development, reinforcing bexobrutideg’s potential as a transformative treatment for B-cell malignancies.
The most recent analyst rating on (NRIX) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Nurix Therapeutics stock, see the NRIX Stock Forecast page.
Spark’s Take on NRIX Stock
According to Spark, TipRanks’ AI Analyst, NRIX is a Neutral.
Nurix Therapeutics’ overall score is driven by strong technical momentum and positive corporate events, offset by weak financial performance and valuation concerns. The company’s strategic initiatives in clinical trials and leadership enhancements are promising, but profitability and cash flow challenges remain significant risks.
To see Spark’s full report on NRIX stock, click here.
More about Nurix Therapeutics
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines for oncology and autoimmune diseases. The company’s pipeline includes degraders of Bruton’s tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B).
Average Trading Volume: 1,619,743
Technical Sentiment Signal: Buy
Current Market Cap: $1.83B
Find detailed analytics on NRIX stock on TipRanks’ Stock Analysis page.